| 1792 |
National Cancer Institute |
Html |
es |
Náuseas y vómitos relacionados con el tratamiento del cáncer (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca de las náuseas y vómitos como complicaciones del cáncer o su tratamiento. Se plantean abordajes de tratamiento de las náuseas y vómitos. |
| radioterapia nombre | 0.366149 |
| Dexametasona Corticosteroides | 0.345517 |
| palonosetrón antagonistas | 0.420992 |
| siguientes tipos | 0.357417 |
| siguientes estrategias | 0.348254 |
| único signo | 0.33198 |
| causa náuseas | 0.753796 |
| National Cancer Institute | 0.339057 |
| determinados medicamentos | 0.5578 |
| siguientes riesgos | 0.330997 |
| quimioterapia nombre | 0.555099 |
| PDQ Acupuntura | 0.392476 |
| Instituto Nacional | 0.371538 |
|
| siguientes problemas | 0.372583 |
| siguientes factores | 0.44966 |
| Physician Data Query | 0.449355 |
| Lorazepam Benzodiazepinas | 0.337793 |
| vómitos tardÃos | 0.949937 |
| siguientes caracterÃsticas | 0.461706 |
| determinadas situaciones | 0.34995 |
| fosaprepitant antagonistas | 0.342662 |
| prometazina fenotiacinas | 0.421253 |
| PDQ Náuseas | 0.567745 |
| medicamento tipo | 0.522815 |
| flujo sanguÃneo escaso | 0.412994 |
| haloperidol butirofenonas | 0.346571 |
|
CLICK HERE |
| 1915 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de intestino delgado (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de intestino delgado. |
| PDQ Tratamiento | 0.7 |
| múltiples ocasiones | 0.771101 |
| siguientes procedimientos | 0.819416 |
| presente sección | 0.734818 |
| tubo gi | 0.768209 |
| Physician Data Query | 0.747544 |
| siguientes tipos | 0.756902 |
| libre uso | 0.701583 |
| rayos x | 0.762021 |
|
| Serie GI | 0.757795 |
| siguientes enlaces | 0.717853 |
| siguientes riesgos | 0.701351 |
| tumores carcinoides | 0.993734 |
| siguientes sumarios | 0.858967 |
| siguientes pruebas | 0.800933 |
| alto contenido | 0.777945 |
| Instituto Nacional | 0.793857 |
|
CLICK HERE |
| 2012 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de pulmón (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar o vigilar el cáncer de pulmón. |
| PDQ Exámenes | 0.778524 |
| Physician Data Query | 0.91448 |
| mayores probabilidades | 0.586703 |
| Estados Unidos | 0.865536 |
| rayos x | 0.605899 |
| prevención revisa | 0.573952 |
| PDQ Prevención | 0.807908 |
| siguientes exámenes | 0.801099 |
| principal causa | 0.623129 |
|
| información ayuda | 0.574441 |
| vÃas respiratorias | 0.622976 |
| National Cancer Institute | 0.606892 |
| siguientes riesgos | 0.571899 |
| PDQ Aspectos | 0.723454 |
| siguientes sumarios | 0.714394 |
| Lung Screening Trial | 0.688089 |
| Instituto Nacional | 0.689164 |
|
CLICK HERE |
| 2018 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de pulmón (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre factores que influyen en el riesgo de presentar cáncer de pulmón y sobre las investigaciones dirigidas a la prevención de esta enfermedad. |
| agentes carcinógenos | 0.462163 |
| factores alimentarios | 0.825457 |
| Retinol Efficacy Trial | 0.359125 |
| Cancer Research Fund | 0.363502 |
| how much | 0.341238 |
| Pinsky PF | 0.34171 |
| Sin embargo | 0.481037 |
| largo plazo | 0.406049 |
| tasas anuales promedio | 0.375764 |
| Health Care Policy | 0.356657 |
| PDQ Consumo | 0.41794 |
| vitaminas antioxidantes e | 0.352553 |
| vitamina e | 0.340093 |
| Outcomes Prevention Evaluation | 0.355777 |
| estudio atbc | 0.383777 |
| Estados Unidos | 0.918409 |
| Natl Cancer Inst | 0.379434 |
| Surgeon General Report | 0.371012 |
| bajo contenido | 0.394946 |
| numerosos estudios | 0.665863 |
| Women’s Health Study | 0.359964 |
| principal factor | 0.344815 |
| verdadera relación causa-efecto | 0.391629 |
| Beta-Carotene Cancer Prevention | 0.361998 |
| altas concentraciones | 0.445954 |
|
| childhood cancer | 0.413412 |
| radón causa | 0.381229 |
| hombres finlandeses fumadores | 0.435889 |
| Multi-Ethnic Cohort Study | 0.379617 |
| Subsequent neoplasms | 0.341756 |
| tabaco causa | 0.392636 |
| alta prevalencia | 0.370255 |
| múltiples lesiones | 0.390734 |
| elementos carcinógenos | 0.375898 |
| Health Study | 0.393239 |
| actividad fÃsica protegen | 0.368641 |
| Data Monitoring Committee | 0.35531 |
| Heart Protection Study | 0.358634 |
| paciente fumador | 0.3962 |
| antecedentes familiares | 0.486318 |
| Cancer Prevention Study | 0.381093 |
| gas radón | 0.368394 |
| principal causa | 0.345807 |
| pacientes fumadores | 0.416554 |
| Cancer Survivor Study | 0.382901 |
| múltiples lesiones premalignas | 0.362501 |
| mayores incrementos | 0.341189 |
| Cancer Prevention | 0.39737 |
| HOPE-The Ongoing Outcomes | 0.356111 |
|
CLICK HERE |
| 2116 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de testículo (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de testículo. |
| accessed july | 0.160067 |
| Task Force reaffirmation | 0.216432 |
| Walsh TJ | 0.2486 |
| accessed october | 0.163022 |
| American Cancer Society | 0.870604 |
| nonseminomatous testicular tumors | 0.345536 |
| Preventive Services Task | 0.945486 |
| Pichlmeier U | 0.270713 |
| Instituto Nacional | 0.34053 |
| benign testicular neoplasms | 0.344213 |
| risk factors | 0.483284 |
| Genitourinary Cancer | 0.306221 |
| PDQ Exámenes | 0.341146 |
| population-based study | 0.15915 |
| Estados Unidos | 0.241886 |
| Natl Cancer Inst | 0.349819 |
| Clinical epidemiology | 0.161836 |
| Testicular carcinoma | 0.320625 |
| Database Syst Rev | 0.192348 |
| Catalona WJ | 0.154934 |
| SEER Cancer Statistics | 0.334649 |
| germ cell neoplasms | 0.219944 |
| Testicular germ-cell | 0.296343 |
| testicular intraepithelial neoplasia | 0.348844 |
| cohort study | 0.156662 |
|
| Cancer Facts | 0.319251 |
| Nat Rev Urol | 0.202726 |
| Hotaling JM | 0.155392 |
| National Cancer Institute | 0.62099 |
| environmental risk factors | 0.226796 |
| Martinus Nijhoff | 0.158009 |
| potencial metastásico | 0.160038 |
| PDQ Tratamiento | 0.296251 |
| riesgo promedio | 0.189608 |
| Misso ML | 0.156367 |
| Intern Med | 0.429314 |
| Cochrane Collaboration | 0.160947 |
| saco vitelino | 0.164571 |
| Clin Oncol | 0.159643 |
| Physician Data Query | 0.188901 |
| Services Task Force | 0.942129 |
| hombres morirán | 0.216745 |
| Arch Intern Med | 0.217716 |
| Schonfeld SJ | 0.155751 |
| germ cell tumors | 0.429551 |
| hombres jóvenes | 0.207617 |
| Male infertility | 0.157895 |
| Sigurdson AJ | 0.156081 |
| caracterÃsticas histológicas benignas | 0.192503 |
|
CLICK HERE |
| 3437 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de estómago (gástrico) (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer de estómago y sobre las investigaciones dirigidas a la prevención de esta enfermedad. |
| siguientes factores | 0.837019 |
| voluntarios sanos | 0.649737 |
| Physician Data Query | 0.828425 |
| siguientes afecciones | 0.700348 |
| Estados Unidos | 0.992286 |
| suficiente ejercicio | 0.665482 |
| prevención revisa | 0.656327 |
| PDQ Prevención | 0.701412 |
| bacteria helicobacter | 0.66365 |
|
| National Cancer Institute | 0.659684 |
| vitamina c | 0.655742 |
| tipo a | 0.654153 |
| siguientes riesgos | 0.647812 |
| alto contenido | 0.74292 |
| siguientes sumarios | 0.735961 |
| vitamina b12 | 0.670397 |
| Instituto Nacional | 0.708301 |
|
CLICK HERE |
| 3561 |
National Cancer Institute |
Html |
en |
Obesity |
People who are obese may have an increased risk of several types of cancer, whereas eating a healthy diet, being physically active, and keeping a healthy weight may help reduce risk of some cancers. |
| National Heart | 0.499901 |
| Obesity | 0.347906 |
| healthy diet | 0.745052 |
| gallbladder | 0.258317 |
| healthy behaviors | 0.755955 |
| Cancer fact sheets | 0.830969 |
| healthy weight | 0.977177 |
| Physical Activity | 0.512739 |
| Overweight | 0.225819 |
| Blood Institute | 0.497718 |
| kidney | 0.214739 |
|
| uterus | 0.266957 |
| menopause | 0.223953 |
| high blood pressure | 0.86289 |
| heart disease | 0.510853 |
| pancreas | 0.241431 |
| cancers | 0.402713 |
| colon | 0.229687 |
| risk | 0.325352 |
| rectum | 0.279116 |
| information | 0.236001 |
|
CLICK HERE |
| 15638 |
National Cancer Institute |
Html |
null |
Cooperative Agreements |
null |
|
|
CLICK HERE |
| 16847 |
National Cancer Institute |
Html |
en |
Safety of Nanotechnology Cancer Treatment |
Nanotechnology is a powerful tool for combating cancer. NCI's Alliance for Nanotechnology in Cancer is continuously testing the safety of this new technology. |
| nanotech applications | 0.677357 |
| animal models | 0.640611 |
| new technology | 0.654112 |
| tissue damage | 0.64104 |
| cancer therapy | 0.659011 |
| ambient incidental nanoparticles | 0.981236 |
| high reactivity | 0.657801 |
| energy consumption | 0.667996 |
| volcanic ash | 0.655357 |
| small size | 0.652566 |
| nanomaterial safety | 0.671123 |
| NCL works | 0.785834 |
| greenhouse gas emissions | 0.807194 |
| nanomaterials | 0.638465 |
| potential health risks | 0.757642 |
| potential toxicity | 0.657709 |
| industrial applications—have | 0.651915 |
| voluntary-consensus standards | 0.640352 |
| powerful tool | 0.664491 |
| physicochemical properties | 0.648003 |
| available data | 0.647533 |
| NCL | 0.841511 |
| NCL tests | 0.795621 |
| unresolved debate | 0.653791 |
| unique tensile | 0.653407 |
|
| specific type | 0.6502 |
| over-the-counter dandruff remedies | 0.781003 |
| drug carriers | 0.640153 |
| potential risks | 0.643319 |
| Nanotechnology Characterization Laboratory | 0.835959 |
| different nanoparticles | 0.793593 |
| NCI Alliance | 0.651255 |
| order-of-magnitude higher levels | 0.778354 |
| nanoparticle exposure studies | 0.785887 |
| intramural program | 0.646486 |
| background incidental nanoparticles | 0.982807 |
| Stone Age | 0.656862 |
| nanomaterial—carbon nanotubes | 0.650728 |
| cancer applications | 0.701263 |
| human activities | 0.656976 |
| household cleaning products | 0.76545 |
| sea spray | 0.653365 |
| animal studies | 0.647308 |
| cancer research communities | 0.992223 |
| toxicity testing | 0.646545 |
| nanomaterial types | 0.658682 |
| medical applications | 0.642559 |
| magnetic properties | 0.653737 |
| family pets | 0.646993 |
|
CLICK HERE |
| 17186 |
National Cancer Institute |
Html |
en |
TMIST (Tomosynthesis Mammographic Imaging Screening Trial) |
TMIST is a randomized breast screening trial that compares two Food and Drug Administration (FDA)-approved types of digital mammography, standard digital mammography (2-D) with a newer technology called tomosynthesis mammography (3-D). |
| routine screening mammogram | 0.506393 |
| entire study group | 0.421549 |
| tomosynthesis mammography | 0.449515 |
| health plans | 0.41281 |
| 3-D mammography | 0.660743 |
| trial | 0.465454 |
| breast cancer status | 0.514295 |
| standard digital mammography | 0.512193 |
| 3-D mammogram | 0.462356 |
| women ages | 0.504522 |
| following factors | 0.42666 |
| breast biopsies | 0.439927 |
| fewer false-positive test | 0.416422 |
| researchers | 0.394009 |
| 2-D screening mammograms | 0.502737 |
| mammography clinics | 0.435449 |
| aggressive breast cancers | 0.493477 |
| ECOG-ACRIN Cancer Research | 0.42875 |
| 2-D mammography | 0.505053 |
| 3-D mammograms | 0.447984 |
| hormone replacement therapy | 0.765582 |
| randomized breast | 0.472367 |
| personal risk factors | 0.42803 |
| primary care doctors | 0.417168 |
| women | 0.662197 |
|
| risk changes | 0.412147 |
| fewer harder-to-treat cancers | 0.422139 |
| study | 0.460399 |
| best ways | 0.450667 |
| mammograms | 0.529145 |
| age group | 0.430585 |
| certain groups | 0.456471 |
| breast cancers | 0.534289 |
| dense breasts | 0.527755 |
| complete cost | 0.412269 |
| premenopausal women | 0.386263 |
| routine mammogram | 0.443785 |
| mammogram | 0.569066 |
| 3-D mammography machines | 0.510266 |
| 3-D mammography images | 0.549905 |
| breast cancer screening | 0.609852 |
| newly diagnosed breast | 0.491574 |
| nearby lymph node | 0.415404 |
| breast cancer | 0.940336 |
| trial record | 0.381013 |
| tissue samples | 0.430822 |
| genetic changes | 0.428717 |
| Women’s health | 0.38389 |
| family history | 0.510755 |
|
CLICK HERE |